active
ACTIVE SINCE: 2020
Back to Collaborations

Development of DNDI-6174 to prevent leishmaniasis

Preclinical development of DNDI-6174, a drug candidate for leishmaniasis
SDGS CONTRIBUTING TO:
SHOW SUB-TARGETS + HIDE SUB-TARGETS -
MEMBER COMPANIES:
PARTNERING WITH:
SEE ALL PARTNER ORGANIZATIONS
Global NGOs 1
Objectives
  • Preclinical development of DNDI-6174, a drug candidate for leishmaniasis

DNDI-6174 presents a new mode of action to the leishmania portfolio as well as good characteristics of compound in the early research stage. It was nominated as a pre-clinical candidate, and Eisai and Drugs for Neglected Diseases initiative (Headquarters: Geneva, Switzerland, “DNDi”) collaborate to prepare the way for future Phase I clinical development.

Results and milestones

DNDi through its Drug Combination Development Platform (DCDP) with its partners is aiming to develop a combination therapy based on newly developed New Chemical Entities (NCEs) to achieve short course therapy with satisfactory efficacy having utility for all regions with disease and avoid emergence of drug resistance. This will improve and simplify current case management and support elimination efforts.

Geographic Reach
  • Global Commitment
Disease Area
  • Infectious and Parasitic Disease
See Disease Areas
Target Population
  • Men
  • Women
  • People with low incomes
Partner organizations
Global NGOs

Drugs for Neglected Diseases initiative (DNDi)

Geographic Reach

Global Commitment

Disease Area

Infectious and Parasitic Disease

  • Neglected Tropical Diseases (NTDs)
    • Leishmaniasis cutaneous and visceral
of